Dr. Lal PathLabs Limited has completed the subscription of a 30% stake in Neuome Technologies Private Limited through its wholly owned subsidiary, Dr. Lal Ventures Private Limited.

The transaction was finalized on August 27, 2026, in accordance with the terms and conditions of the agreement. This move establishes Neuome as an associate company of Dr. Lal PathLabs.

Transaction Details

The Board of Directors of Dr. Lal Ventures had previously approved the stake acquisition in an intimation dated July 24, 2026. The company confirmed that the subscription process concluded on August 27, 2026.

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company also referenced SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, regarding the required intimations.

All necessary disclosures related to this corporate action were included in the earlier communication issued on July 24, 2026. The company requested stock exchanges to record the completion of the transaction.

Dr. Lal Path Labs has incorporated a step-down subsidiary, Dr Lal PathLabs Indomed LLC, in Tashkent, Uzbekistan, to expand its diagnostic services footprint in Central Asia.

The incorporation was executed by Dr Lal PathLabs FZCO, a wholly owned subsidiary of Dr. Lal Path Labs based in Dubai, United Arab Emirates. On August 19, 2026, the Dubai entity agreed to subscribe to 70% of the share capital of the newly formed Tashkent-based company.

Subsidiary details

The key details of the corporate action are as follows:

The establishment of Dr Lal PathLabs Indomed LLC represents a strategic move by Dr. Lal Path Labs to extend its diagnostics presence beyond India into Uzbekistan. The subsidiary will be engaged in providing diagnostic services, aligning with the parent company’s core business line.

The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023. As the entity is newly incorporated, turnover and size metrics are not applicable. No governmental or regulatory approvals are required for this acquisition.